SCHEMBL16193126

SCHEMBL16193126

O=C(Nc1cccc(N2CCOCC2)n1)c1cnc2ccc(N3CCCC(C(F)(F)F)C3)nn12

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 3/20 0.48
▸ DYRK1A Q13627 1/20 0.42
▸ CLK2 P49760 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ CSNK2A1 P68400 1/20 0.41
▸ STK3 Q13188 1/20 0.41
▸ HIPK4 Q8NE63 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ KIF18A Q8NI77 8/20 0.40
▸ PIM1 P11309 1/20 0.39
▸ EIF2AK4 Q9P2K8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ NTRK1 P04629 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ JAK1 P23458 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14882295 0.89 IRAK4 (0.49) IRAK4DYRK1ACLK2GSK3AGSK3B
SCHEMBL14882293 0.89 IRAK4 (0.49) IRAK4DYRK1ACLK2GSK3AGSK3B
SCHEMBL14897641 0.89 IRAK4 (0.49) IRAK4DYRK1ACLK2GSK3AGSK3B
SCHEMBL14897149 0.83 IRAK4 (0.45) IRAK4CLK2GSK3AGSK3BCSNK2A1
SCHEMBL14897445 0.83 IRAK4 (0.45) IRAK4CLK2GSK3AGSK3BCSNK2A1
SCHEMBL14896727 0.83 IRAK4 (0.49) IRAK4PIM1EIF2AK4NTRK1
SCHEMBL14897701 0.82 IRAK4 (0.49) IRAK4NTRK1
SCHEMBL18655143 0.82 IRAK4 (0.46) IRAK4KIF18APIM1EIF2AK4NTRK1
SCHEMBL16193128 0.81 IRAK4 (0.49) IRAK4PIM1EIF2AK4NTRK1
SCHEMBL14897647 0.80 KIF18A (0.45) IRAK4DYRK1ACLK2GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885DYRK1A 2222/4885CLK2 821/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885DYRK1A 2222/4885CLK2 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback